BRIEF-Tianjin Development Posts FY Net Profit Attributable Guidance For Tianjin Lisheng Pharmaceutical

Reuters01-23

BRIEF-Tianjin Development Posts FY Net Profit Attributable Guidance For <a href="https://laohu8.com/S/002393">Tianjin Lisheng</a> Pharmaceutical

Jan 23 (Reuters) - Tianjin Lisheng Pharmaceutical Co Ltd 002393.SZ:

SEES FY NET PROFIT ATTRIBUTABLE FOR TIANJIN LISHENG PHARMACEUTICAL RMB400 MILLION TO RMB440 MILLION

Further company coverage: 002393.SZ

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2605040409?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-23 23:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2605040409","market":"nz","top_or_hot":-1,"title":"BRIEF-Tianjin Development Posts FY Net Profit Attributable Guidance For Tianjin Lisheng Pharmaceutical","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Tianjin Development Posts FY Net Profit Attributable Guidance For <a href=\"https://laohu8.com/S/002393\">Tianjin Lisheng</a> Pharmaceutical</title></head><body><p><span>Jan 23 (Reuters)</span><span> - </span>Tianjin Lisheng Pharmaceutical Co Ltd <span>002393.SZ</span>:</p><ul><li><p>SEES FY NET PROFIT ATTRIBUTABLE FOR TIANJIN LISHENG PHARMACEUTICAL RMB400 MILLION TO RMB440 MILLION</p></li></ul><p>Further company coverage: <span>002393.SZ</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Tianjin Development Posts FY Net Profit Attributable Guidance For Tianjin Lisheng Pharmaceutical</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Tianjin Development Posts FY Net Profit Attributable Guidance For Tianjin Lisheng Pharmaceutical\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-23 23:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Tianjin Development Posts FY Net Profit Attributable Guidance For <a href=\"https://laohu8.com/S/002393\">Tianjin Lisheng</a> Pharmaceutical</title></head><body><p><span>Jan 23 (Reuters)</span><span> - </span>Tianjin Lisheng Pharmaceutical Co Ltd <span>002393.SZ</span>:</p><ul><li><p>SEES FY NET PROFIT ATTRIBUTABLE FOR TIANJIN LISHENG PHARMACEUTICAL RMB400 MILLION TO RMB440 MILLION</p></li></ul><p>Further company coverage: <span>002393.SZ</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260123:nFWN3YO0MG:1","article_id":"2605040409","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2605040409","pubTimestamp":1769181965,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Tianjin Development Posts FY Net Profit Attributable Guidance For Tianjin Lisheng PharmaceuticalJan 23  - Tianjin Lisheng Pharmaceutical Co Ltd 002393.SZ:SEES FY NET PROFIT ATTRIBUTABLE FOR TIANJIN LISHENG PHARMACEUTICAL RMB400 MILLION TO RMB440 MILLIONFurther company coverage: 002393.SZ ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK0239":"医药制造","BK0028":"国家队","BK1232":"复合型公用事业","002393":"力生制药","BK0188":"融资融券","00882":"天津发展"},"translate_title":"简报-天津发展发布天津力生制药财年归属净利润指引","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00882":0.9,"002393":0.9},"content_text":"BRIEF-Tianjin Development Posts FY Net Profit Attributable Guidance For Tianjin Lisheng PharmaceuticalJan 23 (Reuters) - Tianjin Lisheng Pharmaceutical Co Ltd 002393.SZ:SEES FY NET PROFIT ATTRIBUTABLE FOR TIANJIN LISHENG PHARMACEUTICAL RMB400 MILLION TO RMB440 MILLIONFurther company coverage: 002393.SZ ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2605040409","isCrawlerRequest":true}